Patents on therapeutics in developing countries: the challenges ahead

被引:2
作者
Bhalla, Ashish [1 ]
Suri, Vikas
Malhotra, Samir
机构
[1] Postgrad Inst Med Educ & Res, Dept Internal Med, Chandigarh 160012, India
[2] Postgrad Inst Med Educ & Res, Dept Clin Pharmacol, Chandigarh 160012, India
关键词
developing countries; infectious disease; neglected diseases; patents; therapeutics;
D O I
10.1517/13543776.17.8.1015
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Infectious diseases affect those who have limited access to care, but these diseases are no longer a cause of concern for the developing countries alone. Some exotic infections have already started appearing in the developed world, courtesy the AIDS epidemic. The possible misuse of these infectious agents for bioterrorism has further compounded the problem. These threats have forced developed countries to stand up and take notice of these neglected diseases. The collaborative efforts of the international agencies have started yielding some results, but there is still a long way to go. The biggest perceived threat is the patents on therapeutics for these diseases. This article has tried to access the global burden of infectious disease, the threat of patents on therapeutics as perceived by the developing countries and the ongoing international efforts in this regard. The authors also suggest some measures that may help overcome this threat of patents on therapeutics for neglected infectious disease.
引用
收藏
页码:1015 / 1025
页数:11
相关论文
共 55 条
[41]   Is orphan drug status beneficial to tropical disease control? Comparison of the American and future European orphan drug acts [J].
Trouiller, P ;
Battistella, C ;
Pinel, J ;
Pecoul, B .
TROPICAL MEDICINE & INTERNATIONAL HEALTH, 1999, 4 (06) :412-420
[42]   Drug development for neglected diseases: a deficient market and a public-health policy failure [J].
Trouiller, P ;
Olliaro, P ;
Torreele, E ;
Orbinski, J ;
Laing, R ;
Ford, N .
LANCET, 2002, 359 (9324) :2188-2194
[43]  
Velásquez G, 1999, B WORLD HEALTH ORGAN, V77, P288
[44]  
WESTOFF C, 2004, PRB EXECUTIVE SUMMAR
[45]  
*WHO, 1999, INF DIS BIGG KILL YO
[46]  
*WHO, 1975, 28 WORLD HLTH ASS GE, P96
[47]  
*WHO, 1988, WORLD DRUG SIT, P53
[48]  
*WHO, 1999, QUAL ASS PHARM, V1
[49]  
WOLF A, 1994, INSERM, P26
[50]  
World Health Organization, 2007, TOP 10 CAUS DEATH WH